Stocklytics Platform
Asset logo for symbol NAMS
NewAmsterdam Pharma Company N.V.
NAMS46
$15.45arrow_drop_down2.46%-$0.39
Asset logo for symbol NAMS
NAMS46

$15.45

arrow_drop_down2.46%
Key Stats
Open$15.91
Prev. Close$15.84
EPS-2.62
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range15.38
16.07
52 Week Range5.63
26.35
Ratios
EPS-2.62
Fundamentals
EBITDA-
Payout Ratio-
Industry average yield2.90%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

NAMS-
US Healthcare Sector-
US Market-
warning

NAMS / Market

NAMS lose to the US Market which returned 0.79% over the last twenty four hours.
warning

NAMS / Healthcare Sector

NAMS lose to the US Healthcare sector which returned 0.44% over the last twenty four hours.

NewAmsterdam Pharma Company N.V. (NAMS) Statistics

NewAmsterdam Pharma Company N.V. (NAMS) is a pharmaceutical company that specializes in the development and commercialization of innovative drugs. The company is focused on bringing new therapies to market that address unmet medical needs and improve patient outcomes. NAMS is committed to conducting research and clinical trials to advance the understanding and treatment of various diseases.
When it comes to stock statistics, NAMS has shown a strong performance in recent years. The stock has experienced steady growth and has outperformed the sector average. This is reflected in its valuation metrics, which indicate that the stock is undervalued compared to its peers. The stock's fundamentals are also solid, with a healthy profit margin and a low level of total debt.
add NewAmsterdam Pharma Company N.V. to watchlist

Keep an eye on NewAmsterdam Pharma Company N.V.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has NewAmsterdam Pharma Company N.V. (NAMS) stock's performance compared to its sector and the market over the past year?

Over the past year, NewAmsterdam Pharma Company N.V. (NAMS) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 24.45%, NewAmsterdam Pharma Company N.V. has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 63.07%, it has fallen short of the market average. This comparison highlights NewAmsterdam Pharma Company N.V.'s performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of NewAmsterdam Pharma Company N.V. (NAMS) stock?

The PE ratio for NewAmsterdam Pharma Company N.V. (NAMS) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of NewAmsterdam Pharma Company N.V. (NAMS) stock?

The Earnings Per Share (EPS) for NewAmsterdam Pharma Company N.V. (NAMS), calculated on a diluted basis, is -$2.62. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of NewAmsterdam Pharma Company N.V. (NAMS) stock?

The operating margin for NewAmsterdam Pharma Company N.V. (NAMS) is -2.31K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of NewAmsterdam Pharma Company N.V. (NAMS) stock?

Currently, the EBITDA information for NewAmsterdam Pharma Company N.V. (NAMS) is not available. This might be due to various reasons such as the company not disclosing this information for the period in question or recent updates not being reflected.
help

How much debt does NewAmsterdam Pharma Company N.V. (NAMS) have?

NewAmsterdam Pharma Company N.V. (NAMS) has a total debt of $562K. The net debt, which accounts for cash and cash equivalents against the total debt, is -$430.15M.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media